You are here : Home > MAB2 team > Funding

Funding

Published on 2 October 2023

2022-2024
Characterization of the informational value of EG-VEGF as a biomarker of preterm birth in an infectious context
Collaborative project between our team and the laboratory of Pr Guillaume Sébire (Mc Gill University).
Thesis, operation and exchange of researchers are financed by this project.



2022-2024
Characterization of the role of NLRP7 protein in the development and progression of gestational choriocarcinoma




2022-2024
Development of blocking antibodies for PROK system (PCSI- AAP INSERM)
2020-2022
Development and characterization of two monoclonal anti-EG-VEGF and anti-prokineticin receptor antibodies (Inserm Transfert)




2023-2025
Development of therapeutic molecule to inhibit the PROK system
2022-2024
Role of prokineticins in gestational choriocarcinoma
2022-2024
Prokineticins in ovarian cancer




2023-2024
Inflammation in cystic fibrosis: Role of prokineticins
2021-2023
Role of prokineticins in pulmonary inflammation




2021-2023
Characterization of therapeutic molecule to inhibit the PROK system
2020-2024
Development of blocking tools for members of the prokineticin family




2021-2024
EG-VEGF, biomarkers of preeclampsia?




2021-2024
Characterization of brain inflammation




2021-2024
Development of imaging and inhibitor probe for Alzheimer's disease diagnostic and treatment




2021-2024
Characterization of the structure of prokineticins




2023-2026
AVP receptor in preeclampsia: In vitro, in vivo and clinical studies
2021-2025
Development of metal-based agents for selective amyloid imaging




2022-2024
Validation of PROK1 as biomarker of preterm birth (Focus Biomarqueurs CEA)
2022-2023
Role of AVP receptor in preeclampsia (Bottom-up CEA Saclay)





2023-2025
Characterization of neurodevelopment in normal and pathological conditions (CDP IDEX CerCoG@UGA)




​​